Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001415889-25-012489
Filing Date
2025-05-09
Accepted
2025-05-09 16:15:16
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 19864
2 JOINT FILING AGREEMENT ex-99-05092025_080514.htm EX-99.1 11467
  Complete submission text file 0001415889-25-012489.txt   33026
Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 6508505070
Maze Therapeutics, Inc. (Subject) CIK: 0001842295 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94841 | Film No.: 25930608
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 1600 AMPHITHEATRE PKWY MOUNTAIN VIEW CA 94043
Business Address 1600 AMPHITHEATRE PKWY MOUNTAIN VIEW CA 94043 650-335-5278
GV 2019, L.P. (Filed by) CIK: 0001845041 (see all company filings)

EIN.: 384092634 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G